Tmunity is a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T-cell immunotherapy to patients with devastating diseases.
Tmunity represents a new center of gravity in translational T-cell medicine, by integrating a foundational collaboration with the University of Pennsylvania (Penn) with the groundbreaking scientific, clinical, and manufacturing expertise.
Tmunity Therapeutics was founded in 2015 by Carl June, Bruce Blazar, Bruce Levine, Yangbing Zhao, Jim Riley, and Anne Chew. The company is headquartered in Philadelphia, Pennsylvania.
Tmunity is developing a diversified portfolio of novel treatments that exhibit best-in-class control over T-cell activation and direction in the body, with a focus in cancer and three programs currently in clinic development.
Tmunity utilizes laboratories and production facilities at UPenn and its own dedicated cGMP manufacturing facility in Norristown, PA, to pursue process improvement and production scale-up in support of clinical development of T cell therapies.
Tmunity Therapeutics. is backed by Andreessen Horowitz, Westlake Village BioPartners, Gilead Sciences, The University of Pennsylvania, Be The Match BioTherapies and BrightEdge, and others. The company raised $75M from a "Series B" financinng on Oct 31, 2019. This new round brings Tmunity's total funding to $230M to date.